Q2 Holdings Aktie
WKN DE: A1XEYE / ISIN: US74736L1098
29.07.2025 17:51:54
|
Exagen Q2 Revenue Jumps 14 Percent
Exagen (NASDAQ:XGN), a diagnostics company focused on autoimmune conditions, released its second quarter results on July 29, 2025, for the quarter ending June 30. The main headline: revenue (GAAP) beat expectations, climbing to $17.2 million due to expanding sales of its flagship AVISE CTD test, but net loss (GAAP) widened year over year to $4.4 million, and operating expenses rose. Analyst consensus predicted $16.31 million in GAAP revenue and GAAP EPS (earnings per share) of $(0.15), but the EPS (GAAP) result was more negative than expected at $(0.21). The quarter demonstrated robust commercial momentum but highlighted persistent losses as investment in sales, research, and reimbursement efforts continues. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Exagen is a diagnostics company specializing in laboratory tests for autoimmune disorders such as lupus and rheumatoid arthritis. Its main product, AVISE CTD, is a panel of biomarker-based blood tests that help doctors diagnose connective tissue diseases earlier and more accurately. The test accounts for approximately 90% of current annual revenue, underpinning the company's financial results and growth strategy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q2 Holdings Incmehr Nachrichten
29.07.25 |
Ausblick: Q2 veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
06.05.25 |
Ausblick: Q2 legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Q2 Holdings Incmehr Analysen
Aktien in diesem Artikel
Exagen Inc Registered Shs | 9,15 | -1,08% |
|
Q2 Holdings Inc | 57,00 | 0,88% |
|